NASDAQ$ARQT
Arcutis Biotherapeutics Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close · Investor relations
Briefing
Arcutis reported Q4 2025 ZORYVE net product revenue of $127.5 million, up 84% year over year, with quarterly net income of $17.4 million.
Arcutis posted Q4 2025 ZORYVE net product revenue of $127.5 million (+84% YoY, +29% sequentially) and full-year product revenue of $372.1 million (+123%). Total Q4 revenue was $129.5 million with net income of $17.4 million ($0.13 diluted EPS) and positive operating cash flow of $26.2 million. Management raised 2026 net product sales guidance to $480–495 million and highlighted Medicare access, pediatric launches, and Phase 3 pipeline progress.
- Q4 ZORYVE revenue $127.5M (+84% YoY); FY product revenue $372.1M.
- Q4 net income $17.4M; positive operating cash flow $26.2M.
- 2026 product revenue guide raised to $480–495M.
- INTEGUMENT-INFANT Phase 2 positive; sNDA planned Q2 2026.
Headline financials
Revenue & EPS history
Arcutis · Revenue · Quarterly
$130M
Forward guidance
Arcutis guides 2026 ZORYVE net product revenue of $480–495 million, up from prior $455–470 million, with continued expansion in dermatology and targeted primary-care/pediatric commercialization.
Tailwinds
- Profitable quarter with accelerating ZORYVE demand and improved GTN.
- Medicare access for ~one-third of Medicare lives from January 2026.
- Pipeline expansions in atopic dermatitis infants and Phase 3 vitiligo/HS studies.
Headwinds
- SG&A ramp for sales force expansion and Kowa agreement termination transition.
- Payer pricing pressure and gross-to-net dynamics in topical market.
- Clinical and regulatory timing risk on sNDA filings.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
+1.8%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-0.5%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+27.2%
Q3 2025
Best reaction
-15.6%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.2% | -9.3% | -9.4% | |
| Q4 2025 | +5.7% | -12.6% | -21.4% | |
| Q3 2025 | +27.2% | +28.9% | +57.6% | |
| Q1 2025 | -4.6% | +0.5% | +0.3% | |
| Q4 2024 | +8.4% | +5.2% | +28.9% | |
| Q3 2024 | +11.8% | +16.6% | +33.3% | |
| Q2 2024 | -14.6% | -13.1% | +7.1% | |
| Q1 2024 | +15.6% | +15.1% | +16.9% | |
| Q4 2023 | +7.4% | +21.5% | +2.3% | |
| Q3 2023 | +5.4% | -0.9% | -10.4% | |
| Q2 2023 | -2.0% | -6.5% | -21.0% | |
| Q1 2023 | -15.6% | -29.3% | -29.8% | |
| Q4 2022 | +4.4% | -2.7% | -31.8% | |
| Q3 2022 | +0.6% | +3.1% | -8.4% | |
| Q2 2022 | +13.2% | +11.8% | +8.6% | |
| Q1 2022 | -11.8% | -14.1% | -3.5% | |
| Q4 2021 | +1.1% | +12.6% | +10.7% | |
| Q3 2021 | -7.5% | -6.9% | -35.6% | |
| Q2 2021 | +3.1% | +5.2% | +4.1% | |
| Q1 2021 | -3.4% | -1.8% | -23.1% | |
| Q4 2020 | -0.1% | +3.6% | -10.5% | |
| Q3 2020 | -3.8% | +8.9% | +37.1% | |
| Q2 2020 | +1.7% | +1.8% | -6.5% | |
| Q1 2020 | +0.0% | -4.6% | -4.6% | |
| Q4 2019 | +0.0% | -4.6% | -4.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro